and clinical response are disparate. Moreover, unlike IC 50 alone, higher inhibitory potential at peak concentration (IPP), which integrates IC 50 , slope, and C max , correlated with improved complete cytogenetic response (CCyR) rates in CML patients treated with dasatinib. Our findings suggest a metric integrating in vitro and clinical data may provide an improved tool for BCR-ABL mutation-guided TKI selection.
Introduction
BCR-ABL kinase domain mutations represent a common mechanism of resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In vitro cellular IC 50 values have been proposed to guide TKI treatment selection for specific mutations 1 . However, using C max /IC 50 as a measure of potential in vivo activity failed to show correlation with complete cytogenetic response (CCyR) rates in CML patients 2 . Importantly, an IC 50 value constitutes only one point on the dose-response curve for a given drug. Most dose-response curves can be described by Hill's equation (equation 1), which incorporates both IC 50 Here, f a and f u are cell fractions affected and unaffected by treatment, respectively (f u =1-f a ), and D is drug dose. Theoretical and clinical importance of evaluation of the slope in addition to IC 50 has already been shown for antiretroviral drug resistance in HIV 3 . We report estimation of the slope of in vitro dose-response curves for wild-type and kinase domain-mutant BCR-ABL against clinical ABL TKIs for CML and examine the value of this incorporated parameter for predicting clinical response.
Methods
Ba/F3 cellular data Dose response curves for imatinib, nilotinib and dasatinib were determined previously by methanethiosulfonate-based cell viability assay in Ba/F3 cells expressing wild-type or kinase domain-mutant BCR-ABL 4 . Since completely insensitive to all three ABL TKIs tested, the BCR-ABL T315I mutant was excluded from analysis.
Calculation of inhibitory potential values
Logarithmic transformation of the Hill's equation reaches:
The parameters m and IC 50 were determined for each mutation and drug by fitting the equation (2) to the respective dose-response curve using least square sum criterion. Inhibitory potential at peak concentration (IPP) 3 was subsequently calculated as:
Here, D is mean peak concentration (C max ) in plasma as reported.
2
Comparison with clinical response IPP and IC 50 values for each Ba/F3 BCR-ABL mutant were compared with previously reported CCyR rates for nilotinib 8 and dasatinib 9 . Response data for mutations reported in more than 2 patients was included, divided based on mutation IPP and IC 50 values, and CCyR rates were compared between groups by two-tailed Student's t-test with unequal variance (p=0.05 significance threshold). Multivariate analysis was performed by linear multiple regression and the Cox proportional hazard model using JMP-SAS version 10 software (see Supplementary material for details).
Results and Discussion
We fitted Hill's equation to Ba/F3 cell viability dose-response curves for imatinib, nilotinib and dasatinib for wild-type BCR-ABL and each of 15 BCR-ABL kinase domain point mutants (see representative curves in Supplementary Figure 1 ; all data reported in 4 ). Excellent goodness of fit (r 2 values 0.94-0.99) was observed for all drug-mutation pairings. Resultant values of IC 50 and slope for each case are summarized in Table 1 , along with calculated IPP values (see equation 3 in Methods). IPP provides a natural way to combine drug efficacy data in vitro (i.e., IC 50 and slope) with clinical pharmacokinetic data and compare with clinical outcomes.
Imatinib
Most P-loop mutations are reported to render worse response to imatinib 5 . We found that 4 of 7 P-loop mutations tested (G250E, Y253H, E255K, E255V) showed lower dose-response slope relative to wild-type BCR-ABL in addition to high IC 50 (>1100 nM), while all other mutations showed variably increased slopes (Table 1) . Consistent with particularly negative effects of these mutations on drug binding and clinical outcome with imatinib, their lower slopes indicate shallower drug efficacy over a given increase in concentration. Differences in slope values across different resistant mutations likely reflect a varied degree of inhibitor binding destabilization (rather than binding preclusion). Furthermore, the range of IPPs for these mutations was lower than (and not overlapping with) all other mutations (0. (Table 1) . Similarly, the P-loop mutation M244V does not confer marked clinical resistance to imatinib despite increased IC 50 relative to wild-type BCR-ABL, possibly due to an exceptionally high slope value (m=5 vs. m=1.87 for wild-type BCR-ABL) reflecting a very steep dose-response curve (Table 1 ). While at 6000 nM the IPP values for the M244V mutant and wild-type BCR-ABL become virtually identical (5.70 and 5.77, respectively), this concentration is below imatinib C max for some individuals but not others 6 , suggesting patients with this mutation may be particularly vulnerable to consequences of unfavorable imatinib pharmacokinetic profile or reduced compliance. Indeed, one study found clinical resistance to imatinib in 3 out of 6 patients with a M244V mutation was overcome by dose increase 7 .
Nilotinib and Dasatinib
Particularly high slope values (m>4) were found for M244V and Y253F with nilotinib treatment, in contrast to lower values for both mutations with dasatinib treatment (Table 1) .
Comparison of BCR-ABL mutant IPP values between nilotinib and dasatinib revealed favorable, higher IPP for dasatinib over nilotinib against the Y253H mutant; nilotinib demonstrated higher IPP for E255K and F317L compared with dasatinib. For the E255V mutation, both drugs featured low IPPs, consistent with this mutation being reported in clinical failures of both drugs 8, 9 . We next examined whether higher IPP values are predictive of better clinical response. Patient response data was initially divided according to the median mutant IPP value for each TKI. Dasatinib-treated patients with mutations resulting in IPP values above the median (IPP=8) had a significantly higher mean CCyR rate than those patients with mutation IPPs below the median (53% [range 39-80%] vs 31% [range 7-56%]; p=0.038). Notably, using an IPP threshold value of 7 resulted in even better group separation of mean CCyR rate (p=0.007; Figure 1A , see Supplementary Figure 2 for p-values for a range of threshold values). In contrast, this relationship was not evident for mean CCyR rates when IC 50 alone was used as the comparator (p=0.83 for IC 50 values above vs below median IC 50 ; Figure 1B) .
Upon comparison of nilotinib-treated patients by either mutation IPP or IC 50 value, the difference in mean CCyR rate between patients with values above or below the median approached but did not reach statistical significance (p=0.055 for both cases; Figure 1C,D) . Notably, however, both the number of mutations and overall number of nilotinib-treated patients with published available mutation-response data were smaller than for dasatinib (7 vs 11 mutations, 65 vs 295 patients with mutations, respectively).
Multivariate analysis by two methods also demonstrated that a model including IPP and TKI type significantly correlates with CCyR (p<0.001) and outperforms a model that includes IC 50 and slope as separate variables based on the model significance, covariate significance and Akaike information criterion (Supplementary Table 1 ).
In conclusion, we show that in vitro dose-response slope provides important additional information regarding efficacy of ABL TKIs beyond in vitro IC 50 values: lower slopes are indicative of increased resistance, while very high slopes result in a steep dose-response curve presenting potential challenges in cases of low compliance or unfavorable pharmacokinetic profile. Calculation of IPP (based on IC 50 , slope and clinical plasma C max ) allows for separation of patients with respect to rates of CCyR with dasatinib, unlike using in vitro IC 50 alone 2 . Further implementation of our results for improvement of mutationally-guided TKI treatment selection in CML will require incorporation of additional variables such as plasma protein binding, drug clearance and distribution, as well as validation using independent large patient databases. CCyR (%) Figure 1 
